新辅助剂BO-112和具有或没有nivolumab的低分离辐射疗法在软组织肉瘤中:临床前和第一阶段的结果
Jie Deng1, Aastha Pal2, Stefano Testa3
1University of California, Los Angeles Los Angeles United States.
Cancer discovery
|March 5, 2026
概括
结合BO-112,辐射疗法 (RT) 和尼沃卢马布的新辅助疗法在软组织肉瘤 (STS) 中表现有前途. 这种方法可以增强高危患者的抗瘤T细胞反应和疾病控制.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 辐射瘤学 辐射瘤学
背景情况:
- 软组织肉瘤 (STS) 往往缺乏T细胞以进行有效的免疫检查点阻塞 (ICB).
- 在STS瘤中的髓状细胞可以阻碍对放射治疗 (RT) 等标准疗法的反应.
研究的目的:
- 评估新辅助剂BO-112 (纳米复合的多酸:多酸 (多I:C)) 结合低分离RT的安全性和免疫效应,有或没有nivolumab,在高风险STS患者中.
- 评估这种组合在丰富于髓质的STS瘤中克服免疫抵抗的潜力.
主要方法:
- 第1期新辅助试验涉及14名高风险的STS患者.
- 使用BO-112和低分离RT,在某些情况下添加nivolumab.
- 对瘤透免疫细胞,髓状细胞重编程,T细胞疲劳和临床结果的分析.
主要成果:
- 三重组合 (BO-112,RT,nivolumab) 诱导了罕见的免疫相关不良事件,可以通过剂量调整来控制.
- BO-112和RT将髓状细胞重新编程为呈现抗原的表型,并促进T细胞谱的更新.
- 与单独使用标准RT相比,观察到增强的恶性细胞枯竭.
- 在这个小的高风险队列中,发现了令人鼓舞的疾病控制.
结论:
- 新辅助性BO-112和RT组合疗法在STS中表现出强大的免疫活性.
- 这一策略需要对高风险软组织肉瘤进行进一步的临床开发.
- 这种组合显示出增强T细胞介导的抗瘤免疫力在富含髓质细胞的瘤中的潜力.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.4K
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
3.0K
相关概念视频
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K